Literature DB >> 2407079

Metoclopramide: a dopamine receptor antagonist.

J R DiPalma1.   

Abstract

A dopamine receptor antagonist, metoclopramide has unique properties of increasing lower esophageal sphincter pressure and increasing the rate of gastric emptying. These gastrointestinal motility actions are useful in the treatment of diabetic gastroparesis and severe gastroesophageal reflux and in postoperative situations involving visceral atony. Metoclopramide is a useful adjunctive drug for intestinal intubation and radiologic examination. It has also been used intravenously to control the nausea and vomiting of intensive cancer chemotherapy, such as with cisplatin. Metoclopramide is a powerful antiemetic because of its combined actions on the chemoreceptor trigger zone and intestinal motility. This agent is generally not intended for long-term use. The oral preparations are recommended for four to 12 weeks of therapy. Use of parenteral metoclopramide should be limited to one or two days. The most common adverse reactions are restlessness, drowsiness, fatigue and lassitude. Extrapyramidal symptoms occur rarely and only with high dosage or prolonged use.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2407079

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  9 in total

1.  Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6.

Authors:  Mara R Livezey; Erran D Briggs; Amanda K Bolles; Leslie D Nagy; Rina Fujiwara; Laura Lowe Furge
Journal:  Xenobiotica       Date:  2013-09-06       Impact factor: 1.908

2.  Metoclopramide-induced acute dystonic reaction: a case report.

Authors:  Gul Karagoz; Ayten Kadanali; Behiye Dede; Ulker Anadol; Muhterem Yucel; Mehmet Fatih Bektasoglu
Journal:  Eurasian J Med       Date:  2013-02

3.  Investigation of the effect of metoclopramide on proliferation signal molecules in breast tissue.

Authors:  Nurcan Umur; Selda İldan Çalım; Gülce Naz Yazıcı; Seren Gulsen Gurgen
Journal:  Int J Exp Pathol       Date:  2022-03-03       Impact factor: 2.793

Review 4.  Diabetic gastroparesis. A critical reappraisal of new treatment strategies.

Authors:  J P Drenth; L G Engels
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

5.  Nausea and vomiting.

Authors:  Pavan Chepyala; Kevin W Olden
Journal:  Curr Treat Options Gastroenterol       Date:  2008-04

6.  Metoclopramide induced acute dystonic reaction: a case report.

Authors:  Frank-Leonel Tianyi; Valirie Ndip Agbor; Tsi Njim
Journal:  BMC Res Notes       Date:  2017-01-07

7.  Population Pharmacokinetics of Metoclopramide in Infants, Children, and Adolescents.

Authors:  Shufan Ge; Susan R Mendley; Jacqueline G Gerhart; Chiara Melloni; Christoph P Hornik; Janice E Sullivan; Andrew Atz; Paula Delmore; Adriana Tremoulet; Barrie Harper; Elizabeth Payne; Susan Lin; Jinson Erinjeri; Michael Cohen-Wolkowiez; Daniel Gonzalez
Journal:  Clin Transl Sci       Date:  2020-05-27       Impact factor: 4.689

8.  Childhood dystonic reactions in the middle Black Sea region.

Authors:  Sevgi Çirakli
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

9.  Development of acute dystonia in three brothers due to metoclopramide.

Authors:  Ibrahim Silfeler; Vefik Arica; Secil Arica; Murat Dogan
Journal:  J Res Med Sci       Date:  2012-03       Impact factor: 1.852

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.